190 related articles for article (PubMed ID: 30661200)
21. Ceramide conversion to sphingosine-1-phosphate is essential for survival in C3H10T1/2 cells.
Castillo SS; Teegarden D
J Nutr; 2001 Nov; 131(11):2826-30. PubMed ID: 11694603
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of Angiogenesis in Cancer Therapy - Synthesis and Biological Activity.
Gensicka M; Głowacka A; Dzierzbicka K; Cholewinski G
Curr Med Chem; 2015; 22(33):3830-47. PubMed ID: 26337104
[TBL] [Abstract][Full Text] [Related]
23. Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies.
Bach A; Pizzirani D; Realini N; Vozella V; Russo D; Penna I; Melzig L; Scarpelli R; Piomelli D
J Med Chem; 2015 Dec; 58(23):9258-72. PubMed ID: 26560855
[TBL] [Abstract][Full Text] [Related]
24. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.
Mahdy AE; Cheng JC; Li J; Elojeimy S; Meacham WD; Turner LS; Bai A; Gault CR; McPherson AS; Garcia N; Beckham TH; Saad A; Bielawska A; Bielawski J; Hannun YA; Keane TE; Taha MI; Hammouda HM; Norris JS; Liu X
Mol Ther; 2009 Mar; 17(3):430-8. PubMed ID: 19107118
[TBL] [Abstract][Full Text] [Related]
25. Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells.
Liu F; Li X; Lu C; Bai A; Bielawski J; Bielawska A; Marshall B; Schoenlein PV; Lebedyeva IO; Liu K
Oncotarget; 2016 Dec; 7(51):83907-83925. PubMed ID: 27880732
[TBL] [Abstract][Full Text] [Related]
26. Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells.
Shin KO; Seo CH; Cho HH; Oh S; Hong SP; Yoo HS; Hong JT; Oh KW; Lee YM
Arch Pharm Res; 2014; 37(9):1183-92. PubMed ID: 24687256
[TBL] [Abstract][Full Text] [Related]
27. Complete Acid Ceramidase ablation prevents cancer-initiating cell formation in melanoma cells.
Lai M; Realini N; La Ferla M; Passalacqua I; Matteoli G; Ganesan A; Pistello M; Mazzanti CM; Piomelli D
Sci Rep; 2017 Aug; 7(1):7411. PubMed ID: 28785021
[TBL] [Abstract][Full Text] [Related]
28. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.
Cheng JC; Bai A; Beckham TH; Marrison ST; Yount CL; Young K; Lu P; Bartlett AM; Wu BX; Keane BJ; Armeson KE; Marshall DT; Keane TE; Smith MT; Jones EE; Drake RR; Bielawska A; Norris JS; Liu X
J Clin Invest; 2013 Oct; 123(10):4344-58. PubMed ID: 24091326
[TBL] [Abstract][Full Text] [Related]
29. Acid ceramidase, a double-edged sword in cancer aggression: A minireview.
Vethakanraj HS; Chandrasekaran N; Sekar AK
Curr Cancer Drug Targets; 2020 Dec; ():. PubMed ID: 33357194
[TBL] [Abstract][Full Text] [Related]
30. Autophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide.
Turner LS; Cheng JC; Beckham TH; Keane TE; Norris JS; Liu X
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):30-7. PubMed ID: 21116286
[TBL] [Abstract][Full Text] [Related]
31. Acid ceramidase as a therapeutic target in metastatic prostate cancer.
Camacho L; Meca-Cortés O; Abad JL; García S; Rubio N; Díaz A; Celià-Terrassa T; Cingolani F; Bermudo R; Fernández PL; Blanco J; Delgado A; Casas J; Fabriàs G; Thomson TM
J Lipid Res; 2013 May; 54(5):1207-20. PubMed ID: 23423838
[TBL] [Abstract][Full Text] [Related]
32. Identification of cystatin SA as a novel inhibitor of acid ceramidase.
Eliyahu E; Shtraizent N; He X; Chen D; Shalgi R; Schuchman EH
J Biol Chem; 2011 Oct; 286(41):35624-35633. PubMed ID: 21846728
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous quantitative analysis of ceramide and sphingosine in mouse blood by naphthalene-2,3-dicarboxyaldehyde derivatization after hydrolysis with ceramidase.
He X; Dagan A; Gatt S; Schuchman EH
Anal Biochem; 2005 May; 340(1):113-22. PubMed ID: 15802137
[TBL] [Abstract][Full Text] [Related]
34. Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.
Bai A; Bielawska A; Rahmaniyan M; Kraveka JM; Bielawski J; Hannun YA
Bioorg Med Chem; 2018 Dec; 26(23-24):6067-6075. PubMed ID: 30448190
[TBL] [Abstract][Full Text] [Related]
35. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
Gatt S; Dagan A
Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
[TBL] [Abstract][Full Text] [Related]
36. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties.
Pitman MR; Powell JA; Coolen C; Moretti PA; Zebol JR; Pham DH; Finnie JW; Don AS; Ebert LM; Bonder CS; Gliddon BL; Pitson SM
Oncotarget; 2015 Mar; 6(9):7065-83. PubMed ID: 25788259
[TBL] [Abstract][Full Text] [Related]
37. Acid ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of choline kinase α inhibition.
Ramírez de Molina A; de la Cueva A; Machado-Pinilla R; Rodriguez-Fanjul V; Gomez del Pulgar T; Cebrian A; Perona R; Lacal JC
Curr Cancer Drug Targets; 2012 Jul; 12(6):617-24. PubMed ID: 22515519
[TBL] [Abstract][Full Text] [Related]
38. [Sphingosine kinase 1 and tumor].
Zhang CX; He HW; Shao RG
Yao Xue Xue Bao; 2013 Jul; 48(7):971-8. PubMed ID: 24133963
[TBL] [Abstract][Full Text] [Related]
39. A review of ceramide analogs as potential anticancer agents.
Liu J; Beckman BS; Foroozesh M
Future Med Chem; 2013 Aug; 5(12):1405-21. PubMed ID: 23919551
[TBL] [Abstract][Full Text] [Related]
40. Discovery and evaluation of inhibitors of human ceramidase.
Draper JM; Xia Z; Smith RA; Zhuang Y; Wang W; Smith CD
Mol Cancer Ther; 2011 Nov; 10(11):2052-61. PubMed ID: 21885864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
